SSG
REGN icon

Summit Securities Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Summit Securities Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-138
Closed -$107K – 1344
2026
Q1 		$107K Sell
138
-170
-55% -$130K 0.01% 282
2025
Q4 		$238K Buy
308
+280
+1,000% +$190K 0.03% 302
2025
Q3 		$15.7K Buy
+28
New +$15.8K ﹤0.01% 818
2025
Q1 		– Sell
-19
Closed -$13.5K – 1050
2024
Q4 		$13.5K Buy
+19
New +$15.9K ﹤0.01% 413
2024
Q3 		– Sell
-14
Closed -$15K – 812
2024
Q2 		$15K Buy
+14
New +$13.6K ﹤0.01% 411
2024
Q1 		– Sell
-9
Closed -$8K – 812
2023
Q4 		$8K Sell
9
-3
-25% -$2.47K ﹤0.01% 535
2023
Q3 		$10K Sell
12
-23
-66% -$18.1K ﹤0.01% 427
2023
Q2 		$25K Buy
+35
New +$27K ﹤0.01% 578
2022
Q4 		– Sell
-421
Closed -$290K – 1330
2022
Q3 		$290K Buy
+421
New +$265K 0.02% 353
2022
Q2 		– Sell
-481
Closed -$336K – 1183
2022
Q1 		$336K Buy
+481
New +$304K 0.04% 291

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Summit Securities Group's REGN Position: Q2 2026 in Review

Summit Securities Group sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 138 shares — an estimated $107K sold.

Summit Securities Group first reported a position in REGN in Q1 2022 and held it in 10 quarters. The position peaked at $336K in Q1 2022. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Summit Securities Group reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Summit Securities Group sold 138 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $107K.
  • Summit Securities Group first reported a position in Regeneron Pharmaceuticals in Q1 2022 and held it in 10 quarters.
  • Summit Securities Group's Regeneron Pharmaceuticals position peaked at $336K in Q1 2022.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.